In this episode, Joe interviews Dr. Tiago Reis Marques: senior fellow at Imperial College, lecturer at the Institute of Psychiatry, King’s College London, psychiatrist at the Maudsley Hospital, and CEO of Pasithea: a biotech company developing new drugs for the treatment of psychiatric and neurological disorders and offering at-home ketamine infusions (first in New York and California, but soon, all across the US). Marques talks about the importance of repurposing existing drugs due to the insane complexity of the human brain and the myriad of possible problems one can experience, and he talks a lot about ketamine: How it covers a wide range of disorders, the pros and cons of intramuscular ketamine and IV infusions, drug interactions, its similarities with other psychedelics, and the (maybe surprising) lack of side effects. He also discusses the concept of pharmacoeconomic analysis, why new drug development is a very high-risk, high-reward industry, what “responded” means in clinical trials, how Covid-related spikes in PTSD relate to the pandemic timeline, the importance of talking about mental health more, and what we can do with historical and outdated (but important) data.

The post PT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and the Repurposing of Current Drugs appeared first on Psychedelics Today.

Previous articlePsychedelic Bulletin: DEA Proposes Increase to Psilocybin Quota; Field Trip Launches KAP Co-Operative Program; MindMed Files DTx Patent Application
Next articleMindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs to Differentiate Between Their Psychedelic and Non-Psychedelic Effects